NASDAQ:DRRX - Nasdaq - US2666055007 - Common Stock - Currency: USD
0.6101
-0.06 (-8.89%)
The current stock price of DRRX is 0.6101 USD. In the past month the price decreased by -23.74%. In the past year, price decreased by -47.41%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.48 | 831.66B | ||
JNJ | JOHNSON & JOHNSON | 15.46 | 374.37B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.15 | 277.97B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.19 | 222.45B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.85 | 216.81B | ||
MRK | MERCK & CO. INC. | 10.68 | 209.34B | ||
PFE | PFIZER INC | 7.41 | 130.73B | ||
SNY | SANOFI-ADR | 13.7 | 129.16B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.60B | ||
GSK | GSK PLC-SPON ADR | 8.75 | 77.12B | ||
ZTS | ZOETIS INC | 25.94 | 68.50B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.96 | 47.71B |
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. The company is headquartered in Cupertino, California and currently employs 21 full-time employees. The company went IPO on 2000-09-28. The firm is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. The company has developed a proprietary drug product for the treatment of ADHD called Methydur.
DURECT CORPORATION
10240 Bubb Road
Cupertino CALIFORNIA 95014 US
CEO: James E. Brown
Employees: 48
Company Website: https://www.durect.com/
Investor Relations: https://investors.durect.com
Phone: 14087771417
The current stock price of DRRX is 0.6101 USD. The price decreased by -8.89% in the last trading session.
The exchange symbol of DURECT CORPORATION is DRRX and it is listed on the Nasdaq exchange.
DRRX stock is listed on the Nasdaq exchange.
9 analysts have analysed DRRX and the average price target is 6.89 USD. This implies a price increase of 1028.5% is expected in the next year compared to the current price of 0.6101. Check the DURECT CORPORATION stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DURECT CORPORATION (DRRX) has a market capitalization of 18.94M USD. This makes DRRX a Nano Cap stock.
DURECT CORPORATION (DRRX) currently has 48 employees.
DURECT CORPORATION (DRRX) has a resistance level at 0.74. Check the full technical report for a detailed analysis of DRRX support and resistance levels.
The Revenue of DURECT CORPORATION (DRRX) is expected to decline by -94.07% in the next year. Check the estimates tab for more information on the DRRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DRRX does not pay a dividend.
DURECT CORPORATION (DRRX) will report earnings on 2025-05-19.
DURECT CORPORATION (DRRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).
The outstanding short interest for DURECT CORPORATION (DRRX) is 2.53% of its float. Check the ownership tab for more information on the DRRX short interest.
ChartMill assigns a fundamental rating of 3 / 10 to DRRX. DRRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months DRRX reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 76.11% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -45.36% | ||
ROE | -91.16% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to DRRX. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -109.04% and a revenue growth -94.07% for DRRX